Adicet Bio Inc (ACET) - Total Assets
Based on the latest financial reports, Adicet Bio Inc (ACET) holds total assets worth $148.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adicet Bio Inc - Total Assets Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see ACET company net worth for the company's overall valuation and market capitalisation.
Adicet Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Adicet Bio Inc's total assets of $148.17 Million consist of 83.7% current assets and 16.3% non-current assets. Review Adicet Bio Inc (ACET) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $342.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ACET share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adicet Bio Inc's current assets represent 83.7% of total assets in 2025, a decrease from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 22.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Adicet Bio Inc Competitors by Total Assets
Key competitors of Adicet Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Adicet Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.71 | 7.48 | 9.94 |
| Quick Ratio | 6.71 | 7.48 | 9.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $102.76 Million | $110.66 Million | $178.99 Million |
Adicet Bio Inc - Advanced Valuation Insights
This section examines the relationship between Adicet Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -12.7% |
| Total Assets | $192.35 Million |
| Market Capitalization | $84.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adicet Bio Inc's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adicet Bio Inc's assets decreased by 12.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adicet Bio Inc (2008–2025)
The table below shows the annual total assets of Adicet Bio Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $192.35 Million | -12.65% |
| 2024-12-31 | $220.22 Million | +6.23% |
| 2023-12-31 | $207.29 Million | -37.31% |
| 2022-12-31 | $330.69 Million | -2.43% |
| 2021-12-31 | $338.94 Million | +120.33% |
| 2020-12-31 | $153.84 Million | +88.55% |
| 2019-12-31 | $81.59 Million | -25.79% |
| 2018-12-31 | $109.94 Million | +99.19% |
| 2017-12-31 | $55.19 Million | -89.79% |
| 2016-12-31 | $540.78 Million | +10.41% |
| 2015-12-31 | $489.77 Million | +4.66% |
| 2014-12-31 | $467.98 Million | +44.69% |
| 2013-12-31 | $323.43 Million | +8.07% |
| 2012-12-31 | $299.28 Million | +1.45% |
| 2011-12-31 | $294.99 Million | +36.22% |
| 2010-12-31 | $216.56 Million | +14.41% |
| 2009-12-31 | $189.27 Million | -7.90% |
| 2008-12-31 | $205.50 Million | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more